Clinical Trial Update: "MIRO" Molecularly Oriented Immuno-radio-therapy [Phase 2]

View source ↗

Summary

Phase 2 trial update for MIRO molecularly oriented immuno-radio-therapy in follicular lymphoma patients has completed recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Snippet

Sponsor: Fondazione Italiana Linfomi - ETS | Conditions: Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2 | Phase 2 | Status: COMPLETED